🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

83+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 83 recruiting trials for “Glioblastoma

Phase 1, PHASE2RecruitingNCT05664464

Glutamate Inhibitors in Glioblastoma

👨‍⚕️ Hans-Georg Wirsching, MD, University Hospital and University of Zurich📍 1 site📅 Started Jan 2023View details ↗
RecruitingNCT06146725

The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)

👨‍⚕️ Jasper Gerritsen, MD PhD, Erasmus Medical Center📍 8 sites📅 Started Jan 2023View details ↗
RecruitingNCT06273176

The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma

👨‍⚕️ Jasper Gerritsen, MD PhD, Erasmus Medical Center📍 8 sites📅 Started Jan 2023View details ↗
Phase 2RecruitingNCT05565521

UNITy-BasED MR-Linac Adaptive Simultaneous Integrated Hypofractionated Boost Trial for High Grade Glioma in the Elderly

🏥 Sunnybrook Health Sciences Centre📍 1 site📅 Started Dec 2022View details ↗
EARLY_Phase 1RecruitingNCT05423210

Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme

👨‍⚕️ Alexander Stessin, MD, Stony Brook Cancer Center📍 1 site📅 Started Oct 2022View details ↗
Phase 1RecruitingNCT05303467

A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

👨‍⚕️ Riad Salem, M.D., Northwestern University📍 9 sites📅 Started Jul 2022View details ↗
NARecruitingNCT05186064

Glioblastoma Targeted Treatment Option Maximization by WGS

🏥 UMC Utrecht📍 1 site📅 Started Jul 2022View details ↗
Phase 3RecruitingNCT05271240

Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM

👨‍⚕️ John Boockvar, MD, Feinstein Institute for Medical Research/Lenox Hill Hospital📍 1 site📅 Started Apr 2022View details ↗
RecruitingNCT06118723

The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)

👨‍⚕️ Jasper Gerritsen, MD PhD, Erasmus Medical Center📍 8 sites📅 Started Jan 2022View details ↗
Phase 2RecruitingNCT04523688

Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma

👨‍⚕️ Laura Ridolfi, DR, IRST IRCCS📍 1 site📅 Started Mar 2021View details ↗
Phase 1RecruitingNCT04541082

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

🏥 Jazz Pharmaceuticals📍 1 site📅 Started Oct 2020View details ↗
Phase 1RecruitingNCT04323046

Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults

👨‍⚕️ Tom Davidson (tdavidson@chla.usc.edu), MD, Children's Hospital Los Angeles📍 20 sites📅 Started Oct 2020View details ↗
Phase 1RecruitingNCT04555577

Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma

👨‍⚕️ Nazanin Majd, MD, M.D. Anderson Cancer Center📍 1 site📅 Started Sep 2020View details ↗
NARecruitingNCT02613988

Advanced MR Imaging as Predictor of Treatment Response in Newly Diagnosed Glioblastomas

👨‍⚕️ Ho Sung Kim, MD, PhD, Asan Medical Center📍 1 site📅 Started Jan 2020View details ↗
Phase 2, PHASE3RecruitingNCT03970447

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

👨‍⚕️ Tim Cloughesy, MD, GCAR CMO and GBM AGILE Global PI📍 62 sites📅 Started Jul 2019View details ↗
NARecruitingNCT03144167

Study of Prognostic Biomarkers of Survival at 6 Months for Patients Treated With Bevacizumab Glioblastomas in First Relapse After Failure of Radiochemotherapy

🏥 Centre Hospitalier Universitaire, Amiens📍 1 site📅 Started Jun 2019View details ↗
Phase 1RecruitingNCT03423628

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

👨‍⚕️ Patrick Wen, Dana-Farber Cancer Institute📍 12 sites📅 Started Apr 2018View details ↗
Phase 1, PHASE2RecruitingNCT03382977

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

👨‍⚕️ Francisco Diaz-Mitoma, MD, Variation Biotechnologies Inc.📍 12 sites📅 Started Dec 2017View details ↗
Phase 1, PHASE2RecruitingNCT03213002

Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

👨‍⚕️ John Boockvar, MD, Lenox Hill Hospital-Northwell Health📍 1 site📅 Started Jun 2017View details ↗
Phase 1Enrolling by InvitationNCT03170141

Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme

👨‍⚕️ Lung-Ji Chang, PhD, Shenzhen Geno-Immune Medical Institute📍 1 site📅 Started May 2017View details ↗
← PreviousPage 4 of 5Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →